T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

This study is testing a combination of personalized immune cells (called T cells) engineered to fight brain tumors, together with the immunotherapy drug pembrolizumab, in patients with glioblastoma — one of the most aggressive forms of brain cancer — both newly diagnosed and recurrent cases. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with glioblastoma (grade 4 brain tumor) confirmed by biopsy - Your diagnosis may be a new diagnosis or a recurrence - You meet the general health and organ function requirements **You may NOT be eligible if...** - You are under 18 years old - You have not had a confirmed tissue diagnosis of glioblastoma - You have conditions that make immunotherapy unsafe - Your health status or organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.